Predict your next investment

Ruike Biotechnology company logo
HEALTHCARE | Biotechnology
recbio.cn

See what CB Insights has to offer

Founded Year

2012

Stage

Series C | Alive

Total Raised

$256.3M

Last Raised

$156.3M | 1 mo ago

About Ruike Biotechnology

Ruike Biotechnology has developed a product pipeline covering a series of human papillomavirus vaccines (HPV), recombinant zoster vaccines (RZV), vaccines for the prevention and treatment of tuberculosis, and recombinant COVID vaccines at different R&D phases.

Ruike Biotechnology Headquarter Location

China Medicine City Suite A217

Taizhou, Jiangsu, 225300,

China

86 523 86818860

Latest Ruike Biotechnology News

China's Alcha Rallies on Service Deal for Ruike's Covid-19 Vaccine Plant China's Alcha Rallies on Service Deal for Ruike's Covid...

Dec 15, 2020

(Yicai Global) Dec. 15 -- Shares of Alcha Aluminum Group surged today after the Chinese alloy products maker said that its unit will help prepare Ruike Biotechnology's new plant to produce Covid-19 vaccines. Alcha's stock price [SHE:002160] jumped by the daily limit of 10 percent to CNY4.18 (US 60 cents) this morning with a CNY3 billion (USD457.6 million) market cap. Macroprocess Lustration Technology inked an engineering service contract with Jiangsu province-based Ruike Biotechnology to install equipment and clean the premises at the latter's plant in eastern China's Taizhou, the Changshu-based firm said in a statement yesterday, without disclosing more timing or financial details. Ruike Biotechnology began building its vaccine factory in Taizhou in late November, according to Taizhou Daily. The recombinant protein vaccine is expected to enter phase I clinical trial in January 2021 and to kick off phase III in April. After that, the product should hit global markets in the second half of 2021, according to the same report. The project will help increase Alcha’s influence in the medical cleaning market and improve its future operating results, the company added. Editor: Emmi Laine

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Ruike Biotechnology

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Ruike Biotechnology is included in 2 Expert Collections, including Infectious Disease.

I

Infectious Disease

2,330 items

Entities aiding the surveillance, screening, prevention, diagnosis, treatment, and containment of infections & the maintenance of public wellbeing during outbreaks.

B

Biopharmaceuticals

5,726 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.